Total population | Primary aldosteronism | No primary aldosteronism | |
---|---|---|---|
(n = 824) | (n = 40) | (n = 784) | |
Age (years) | 53.2 (13.3) | 53.9 (10.1) | 53.2 (13.5) |
Sex (female) | 405 (49%) | 8 (20%) | 397 (51%) |
Family history of hypertension | 510 (66%) | 27 (69%) | 483 (66%) |
Office blood pressure (mmHg) | 171/98 (26/14) | 168/103 (21/13) | 171/98 (26/14) |
Office heart rate (bpm) | 74 (14) | 68 (10) | 74 (14) |
24-h ambulatory blood pressure (mmHg) | 144/86 (17/11) | 149/90 (16/8) | 144/86 (17/12) |
Dipping (%)a | 11 (7) | 10 (7) | 11 (7) |
Number of antihypertensive medication classesb | 2 (1–3) | 2 (1–3) | 2 (1–3) |
ACE-inhibitor / ARB / direct renin inhibitor | 572 (69%) | 27 (68%) | 545 (70%) |
Diuretic | 385 (47%) | 18 (45%) | 367 (47%) |
Potassium-sparing diuretic | 22 (3%) | 0 (0%) | 22 (3%) |
Mineralocorticoid antagonist | 93 (11%) | 6 (15%) | 87 (11%) |
BMI (kg/m2) | 28 (5) | 30 (4) | 28 (5) |
HbA1c (mmol/mol) | 37 (33–40) | 36 (33–39) | 37 (33–40) |
Probable obstructive sleep apneac | 125 (19%) | 11 (34%) | 114 (19%) |
Serum sodium (mmol/L) | 139 (3) | 140 (2) | 139 (3) |
Serum potassium (mmol/L) | 3.9 (0.4) | 3.5 (0.5) | 4.0 (0.4) |
Hypokalemia (< 3.5 mmol/L) | 40 (11%) | 9 (45%) | 31 (9%) |
Potassium supplementation | 9 (1%) | 3 (8%) | 6 (1%) |
eGFR (mmol/L/1.73m2)d | 84 (20) | 83 (20) | 84 (20) |
Albuminuria category 2 (ACR 3–30 mg/mmol) | 117 (19%) | 10 (30%) | 107 (19%) |
Albuminuria category 3 (ACR > 30 mg/mmol) | 25 (4%) | 3 (9%) | 22 (4%) |
Use of escape medication | 176 (22%) | 14 (36%) | 162 (21%) |
Aldosterone/renin ratio > 5 pmol/fmol/s | 137 (17%) | 40 (100%) | 97 (12%) |
Plasma aldosterone after salt loading test (pmol/L) | 170 (90–290) | 365 (310–635) | 110 (70–180) |
Fulfill Endocrine Society Guideline Criteria | 687 (94%) | 34 (100%) | 653 (93%) |